Triplex Pharmaceutical

Basic Information

9391 Grogans Mill Road
The Woodlands, TX, 77380

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: Y
Woman Owned: N
Number of Employees: n/a


  1. Development of a Novel Anti-HIV Oligonucleotide

    Amount: $98,800.00

    AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haa ...

    SBIR Phase I 1995 Department of Health and Human Services
  2. Development of a Novel Cytomegalovirus Drug

    Amount: $100,000.00

    Cytomegalovirus (CMV) causes severe infections in infants, organ transplant recipients and AIDS patlong term objective of this work is to treat humans who have cytomegalovirus infections with a novels ...

    SBIR Phase I 1995 Department of Health and Human Services
  3. Active Anti-HIV Guanosine/Thymidine Oligonucleotides

    Amount: $100,000.00

    We will develop a new class of oligonucleotides, which fold themselves into ordered structures andmainly of deoxyguanosine and deoxythymidine (GTOs), as therapeutic antiviral agents active against HGT ...

    SBIR Phase I 1995 Department of Health and Human Services
  4. Alkenylguanine Analogs--A New Class of Antiviral Agent

    Amount: $100,000.00

    We will develop certain structure activity relationships with respect to a novel class of antiviralconduct preliminary experiments designed to define the mechanism of action for these drugs. Prelimine ...

    SBIR Phase I 1995 Department of Health and Human Services
  5. New Delivery Systems for Therapeutic Oligonucleotides

    Amount: $100,000.00

    Antisense and triple helix-forming oligonucleotides (TFOs) have great potential as therapeutic agenspecifically block the expression of deleterious genes. We will develop novel delivery vehicles, toin ...

    SBIR Phase I 1995 Department of Health and Human Services
  6. Oligonucleotides Inhibition of HIV-1 Integrase

    Amount: $65,956.00

    Effective therapy for human immunodeficiency virus (HIV) infection remains elusive, partly dueto the fact that infected long lived cells provide a reservoir for the virus. Currently availableanti-retr ...

    SBIR Phase I 1994 Department of Health and Human Services
  7. Enhanced Efficacy of Triplex Oligonucleotides

    Amount: $50,000.00

    We will develop a novel class of therapeutics based on Triple-Helix Forming Oligonucleotides (TFOs). Attachment of lipophilic groups to anti-cancer and anti- HSV-2 TFOs will be examined to enhance the ...

    SBIR Phase I 1993 Department of Health and Human Services
  8. Triplex Inhibition of Progesterone Receptor

    Amount: $50,000.00

    Triple helix formation between duplex DNA and oligonucleotides has been observed for over twenty years for synthetic polymers and more recently for genomic DNA. Triplex formation prevents the associat ...

    SBIR Phase I 1993 Department of Health and Human Services
  9. Anti-HCMV Activity of Triple Helix-Forming Oligos

    Amount: $40,000.00

    The aim is to test the feasibility of using triple helix (triplex)-forming oligonucleotides as antiviral agents against human cytomegalovirus. Oligonucleotides have long been known to be capable of bi ...

    SBIR Phase I 1993 Department of Health and Human Services
  10. MODIFIED NUCLEOSIDES IN TRIPLEX FORMING OLIGONUCLEOTIDES

    Amount: $50,000.00

    THE PRIMARY GOAL OF THIS STUDY IS TO CHEMICALLY REFINE A CLASS OF SEQUENCE-SPECIFIC, DNA BINDING, TRIPLE HELIX-FORMING OLIGONUCLEOTIDES (TFOS). THE UNIQUE FEATURE OF THESE TFOS IS THAT BINDING OF THE ...

    SBIR Phase I 1992 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government